Research
Hormonal
Semaglutide 2.4 mg reduces body weight by an estimated mean change ranging from -9.40% to -16.42% in an East Asian population.
Practitioners can consider semaglutide 2.4 mg as an effective option for weight loss in East Asian adults with obesity.
StrongSupportsmedium confidence
the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %.
Why this rating
Based on the randomized controlled trial design of STEP 6.
Source
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis
Takashi Kadowaki et al. · Obesity Research & Clinical Practice · 2024
DOI 10.1016/j.orcp.2025.01.002
rct · n=401Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →